Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients - Wikidata - wikimedia - TriplyDB

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients

http://www.wikidata.org/entity/Q34413103

about

Delayed-onset cytomegalovirus disease coded during hospital readmission in a multicenter, retrospective cohort of liver transplant recipients.Cytomegalovirus infection in liver transplant recipients: updates on clinical management Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.

P2860

Q35985337-A1141D78-F8E5-4352-9CDD-9238C30776B5 Q38242802-2036A52E-C8A9-4358-BAC5-484C9A6FEA6C Q38293175-8FA5EED4-C8C5-4128-A0D6-E065D6430842

P2860

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients

http://www.wikidata.org/entity/Q34413103

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Valganciclovir is an effective ...... in liver transplant recipients

@ast

Valganciclovir is an effective ...... in liver transplant recipients

@en

Valganciclovir is an effective ...... in liver transplant recipients

@nl

type

label

Valganciclovir is an effective ...... in liver transplant recipients

@ast

Valganciclovir is an effective ...... in liver transplant recipients

@en

Valganciclovir is an effective ...... in liver transplant recipients

@nl

prefLabel

Valganciclovir is an effective ...... in liver transplant recipients

@ast

Valganciclovir is an effective ...... in liver transplant recipients

@en

Valganciclovir is an effective ...... in liver transplant recipients

@nl

P1433

Q34413103-6ECEEDA0-E89F-442A-9B79-139221280270

P1476

Q34413103-5164FCC7-94DC-4FCE-8553-1C3E1F3B102E

P2093

Q34413103-0044E3AE-3B63-4A81-8C2B-413009D9E39B

Q34413103-26E65282-9EB8-4B26-9573-2DF0BA1009E9

Q34413103-B590F9EC-4283-4223-AC41-824A9898EAA4

Q34413103-CB944171-4A00-45D2-B024-3A81264034A4

Q34413103-D0FEB495-12A4-4B13-8707-4E63D08BC81B

Q34413103-D36F62FE-27FC-4CD9-BD67-A63D92F12D28

P2860

Q34413103-09571BC7-C911-4A02-8994-231CD3F47098

Q34413103-319AD4A5-C461-4DF0-9046-3B9D7CFB8AF5

Q34413103-460731BD-D0E8-4D2D-AC96-16EE77A5A4C0

Q34413103-5231E308-0366-475E-A420-E8094527259A

Q34413103-54A874D2-C0C7-4FF0-82D9-99BE6E95F57C

Q34413103-54D47DDC-87D9-4737-A03C-A3044637A3E3

Q34413103-55C47E41-5CA8-41AB-8F0A-0E2B69D8BD0D

Q34413103-63924AE8-B182-429B-8785-24042B72EAAE

Q34413103-76840021-2D6B-4938-8E95-BDF44BCC8AE4

Q34413103-91324E0E-9DED-45EE-9869-68355CE5A212

P304

Q34413103-3934B07C-37D3-48DA-B235-E4A89F708E26

P31

Q34413103-B6138A6B-EABC-4B61-B2E4-030F42E92B87

P356

Q34413103-EAA71E71-B5B1-4C45-AB6E-574F0AC04ADE

P433

Q34413103-E554352E-2425-40A0-BC0C-FA72898B5102

P478

Q34413103-9336FFE9-12A2-4FC4-9DA5-CC1ADAFF5D9C

P577

Q34413103-F5451E2E-2334-472D-8A5D-D58B42656C04

P5875

Q34413103-5D20D0A4-09D3-4E67-8BCE-FFE4E1CE5D31

P698

Q34413103-FE4A93BD-96C8-485E-863C-B6411B958C3F

P921

Q34413103-1B440E99-F96F-4D52-9D75-E7FF7480C33D

P932

Q34413103-A3168802-61A8-48ED-A816-19A4811D10B7

P356

J.1477-2574.2010.00226.X

P1433

Hepato Pancreato Biliary

P1476

Valganciclovir is an effective ...... in liver transplant recipients

@en

P2093

Benjamin Philosophe

http://www.w3.org/2001/XMLSchema#string

Flavia Rasetto

http://www.w3.org/2001/XMLSchema#string

Raghava Munivenkatappa

http://www.w3.org/2001/XMLSchema#string

Rolf N Barth

http://www.w3.org/2001/XMLSchema#string

Sameh Adel Fayek

http://www.w3.org/2001/XMLSchema#string

Wana Mantipisitkul

http://www.w3.org/2001/XMLSchema#string

P2860

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.

Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.

Benefits of cytomegalovirus prophylaxis in solid organ transplantation.

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.

CMV infection, diagnosis and antiviral strategies after liver transplantation.

Overview of patient compliance with medication dosing: a literature review.

Cytomegalovirus infection after liver transplantation: current concepts and challenges.

Delayed-onset primary cytomegalovirus disease after liver transplantation.

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytom

P304

657-663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1477-2574.2010.00226.X

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47811147

http://www.w3.org/2001/XMLSchema#string

P698

21083790

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

3003475

http://www.w3.org/2001/XMLSchema#string